PMID- 30754166
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 7
IP  - 4
DP  - 2012 Jul
TI  - Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role 
      for controlling glycemic variability.
PG  - 395-405
LID - 10.1586/eem.12.35 [doi]
AB  - There is a growing body of evidence to illustrate the effect of postprandial 
      hyperglycemia (PPHG) in cardiovascular disease development and as a key component 
      of diurnal hyperglycemia. Agents such as acarbose, which has been shown to reduce 
      24-h glycemia and glycated hemoglobin (mainly via its effects on PPHG), may have 
      the potential to reduce the risk of adverse cardiovascular outcomes as indicated 
      in secondary analyses of the STOP-NIDDM trial. Although the results of the 
      NAVIGATOR trial showed no effect of PPHG reduction on cardiovascular outcomes, 
      acarbose has a different mode of action to nateglinide. This could lead to marked 
      cardiovascular differences, and it is important to fully investigate this. The 
      ongoing ACE trial will determine the effect of acarbose on a composite primary 
      end point of cardiovascular outcomes.
FAU - Hanefeld, Markolf
AU  - Hanefeld M
AD  - a Center for Clinical Studies, GWT - Technical University Dresden, Fiedlerstrasse 
      34, 01307 Dresden, Germany. hanefeld@gwtonline-zks.de.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
OTO - NOTNLM
OT  - PPHG
OT  - Type 2 diabetes
OT  - acarbose
OT  - cardiovascular disease
OT  - glycemic variability
EDAT- 2012/07/01 00:00
MHDA- 2012/07/01 00:01
CRDT- 2019/02/14 06:00
PHST- 2019/02/14 06:00 [entrez]
PHST- 2012/07/01 00:00 [pubmed]
PHST- 2012/07/01 00:01 [medline]
AID - 10.1586/eem.12.35 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2012 Jul;7(4):395-405. doi: 10.1586/eem.12.35.